Bernard Moss MD Ph.D.
NIH Distinguished Investigator, Chief Laboratory of Viral Diseases
Join to View Full Profile
33 North DriveBuilding 33Bethesda, MD 20892
Dr. Moss is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
New York University School of MedicineClass of 1961
Publications & Presentations
PubMed
- 85 citationsVirulence differences of mpox (monkeypox) virus clades I, IIa, and IIb.1 in a small animal model.Jeffrey L Americo, Patricia L Earl, Bernard Moss
Proceedings of the National Academy of Sciences of the United States of America. 2023-02-21 - 12 citationsInhibition of vaccinia virus L1 N-myristoylation by the host N-myristoyltransferase inhibitor IMP-1088 generates non-infectious virions defective in cell entry.Lalita Priyamvada, Wouter W Kallemeijn, Monica Faronato, Kimberly Wilkins, Cynthia S Goldsmith
Plos Pathogens. 2022-10-01 - 19 citationsIntranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection.Jeffrey L Americo, Catherine A Cotter, Patricia L Earl, Ruikang Liu, Bernard Moss
Proceedings of the National Academy of Sciences of the United States of America. 2022-06-14
Journal Articles
- RNA Polymerase Mutations Selected During Experimental Evolution Enhance Replication of a Hybrid Vaccinia Virus with an Intermediate Transcription Factor Subunit Replac...Bernard Moss, MD, mBio
Press Mentions
Moving TargetSeptember 16th, 2022- GeoVax Announces Issuance of Hepatitis B Vaccine PatentJuly 7th, 2021
- GeoVax Receives Notice of Allowance for Hepatitis B Vaccine PatentApril 1st, 2021
- Join now to see all
Grant Support
- Recombinant Virus VaccinesNATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESPresent
- Poxvirus BiologyNATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESPresent
- Development of a SARS-CoV-2 vaccineNATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESPresent
- Poxvirus BiologyNATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESPresent
- Recombinant Virus VaccinesNATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESPresent
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
